These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35000652)

  • 21. Pharmacologic treatment of body dysmorphic disorder.
    Phillips KA
    Psychopharmacol Bull; 1996; 32(4):597-605. PubMed ID: 8993080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body Dysmorphic Disorder in Women.
    Phillips KA; Susser LC
    Psychiatr Clin North Am; 2023 Sep; 46(3):505-525. PubMed ID: 37500247
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Body dysmorphic disorder: Symptoms, prevalence, assessment and treatment].
    Hardardottir H; Hauksdottir A; Bjornsson AS
    Laeknabladid; 2019 Mar; 105(3):125-131. PubMed ID: 30806630
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
    Phillips KA; Albertini RS; Rasmussen SA
    Arch Gen Psychiatry; 2002 Apr; 59(4):381-8. PubMed ID: 11926939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapist guided internet based cognitive behavioural therapy for body dysmorphic disorder: single blind randomised controlled trial.
    Enander J; Andersson E; Mataix-Cols D; Lichtenstein L; Alström K; Andersson G; Ljótsson B; Rück C
    BMJ; 2016 Feb; 352():i241. PubMed ID: 26837684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Body dysmorphic disorder].
    Grau K; Fegert JM; Allroggen M
    Z Kinder Jugendpsychiatr Psychother; 2015 Jan; 43(1):29-35; quiz 36-7. PubMed ID: 25536894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Body dysmorphic disorder: Future prospects of medical care].
    Siegfried E; Ayrolles A; Rahioui H
    Encephale; 2018 Jun; 44(3):288-290. PubMed ID: 29102368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder: A Double-Blind, Placebo-Controlled Trial.
    Phillips KA; Keshaviah A; Dougherty DD; Stout RL; Menard W; Wilhelm S
    Am J Psychiatry; 2016 Sep; 173(9):887-95. PubMed ID: 27056606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunctive antipsychotic in the treatment of body dysmorphic disorder - A retrospective naturalistic case note study.
    Rashid H; Khan AA; Fineberg NA
    Int J Psychiatry Clin Pract; 2015 Jun; 19(2):84-9. PubMed ID: 25363200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acute trajectories of neural activation predict remission to pharmacotherapy in late-life depression.
    Karim HT; Wang M; Andreescu C; Tudorascu D; Butters MA; Karp JF; Reynolds CF; Aizenstein HJ
    Neuroimage Clin; 2018; 19():831-839. PubMed ID: 30013927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy and psychotherapy for body dysmorphic disorder.
    Ipser JC; Sander C; Stein DJ
    Cochrane Database Syst Rev; 2009 Jan; 2009(1):CD005332. PubMed ID: 19160252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining machine learning algorithms for prediction of antidepressant treatment response.
    Kautzky A; Möller HJ; Dold M; Bartova L; Seemüller F; Laux G; Riedel M; Gaebel W; Kasper S
    Acta Psychiatr Scand; 2021 Jan; 143(1):36-49. PubMed ID: 33141944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prediction of early improvement of major depressive disorder to antidepressant medication in adolescents with radiomics analysis after ComBat harmonization based on multiscale structural MRI.
    Ma H; Zhang D; Wang Y; Ding Y; Yang J; Li K
    BMC Psychiatry; 2023 Jun; 23(1):466. PubMed ID: 37365541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of Multimodal Treatment for Young People With Body Dysmorphic Disorder in Two Specialist Clinics.
    Rautio D; Gumpert M; Jassi A; Krebs G; Flygare O; Andrén P; Monzani B; Peile L; Jansson-Fröjmark M; Lundgren T; Hillborg M; Silverberg-Mörse M; Clark B; Fernández de la Cruz L; Mataix-Cols D
    Behav Ther; 2022 Sep; 53(5):1037-1049. PubMed ID: 35987534
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Body dysmorphic disorder: beyond skin deep.
    Husain Z; Janniger EJ; Krysicka JA; Micali G; Schwartz RA
    G Ital Dermatol Venereol; 2014 Aug; 149(4):447-52. PubMed ID: 25068234
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic treatment of body dysmorphic disorder: review of the evidence and a recommended treatment approach.
    Phillips KA
    CNS Spectr; 2002 Jun; 7(6):453-60, 463. PubMed ID: 15107767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predicting treatment response using EEG in major depressive disorder: A machine-learning meta-analysis.
    Watts D; Pulice RF; Reilly J; Brunoni AR; Kapczinski F; Passos IC
    Transl Psychiatry; 2022 Aug; 12(1):332. PubMed ID: 35961967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Risk Prediction Model for Physical Restraints Among Older Chinese Adults in Long-term Care Facilities: Machine Learning Study.
    Wang J; Chen H; Wang H; Liu W; Peng D; Zhao Q; Xiao M
    J Med Internet Res; 2023 Apr; 25():e43815. PubMed ID: 37023416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An open-label trial of venlafaxine in body dysmorphic disorder.
    Allen A; Hadley SJ; Kaplan A; Simeon D; Friedberg J; Priday L; Baker BR; Greenberg JL; Hollander E
    CNS Spectr; 2008 Feb; 13(2):138-44. PubMed ID: 18227745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.